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SHORT REPORT Open Access
Sputum matrix metalloproteinase-9 is associated
with the degree of emphysema on computed
tomography in COPD
Rekha Chaudhuri1, Charles McSharry1, Mark Spears1, Jeffrey Brady2,3,4, Christal Grierson2,3,4, C Martina Messow5,
Gino Miele2,3,4, Karl Nocka2,3,4, William MacNee6, Martin Connell6, John T Murchison6, Michael Sproule7,
Omar Hilmi8, Douglas K Miller2,3,4 and Neil C Thomson1*
Abstract
Background: Matrix-metalloproteinase (MMP)-9 has been implicated in the pathogenesis of COPD, although its link
to disease severity is unclear. The purpose of the study was to examine the relationship between disease severity
assessed by lung function and computed tomography (CT) and sputum MMP-9 expression, concentration and
activity in patients with COPD.
Findings: In 53 COPD subjects, smokers and ex-smokers; 46 healthy controls, smokers and never smokers, we
measured sputum MMP-9 concentrations (ELISA) and enzyme activity (FRET), sputum MMP-9 mRNA expression,
spirometry, diffusing capacity for carbon monoxide (DLco) and CT assessment of emphysema (% low attenuation
areas below-950 Hounsfield units).
Sputum MMP-9 concentrations and mRNA expression in COPD subjects were significantly greater than in healthy
never-smokers (p = 0.007 and p = 0.001 respectively) and similar to those in healthy smokers. Disease severity when
assessed by the extent of emphysema measured by CT, but not by spirometry or DLco values, was directly associated
with sputum MMP-9 concentrations [r = 0.442 (0.171, 0.634), p = 0.020], and MMP-9 activity [r = 0.447 (0.219, 0.643),
p = 0.010]. In moderate to severe COPD, increased MMP-9 mRNA expression levels were associated with reduced
post-bronchodilator FEV1 [r = −0.530 (−0.686, -0.327), p < 0.001], FEV1/FVC ratio [r = −0.551 (−0.701, -0.354), p < 0.001]
and reduced DLco [r = −0.399 (−539, -0.102), p = 0.048].
Conclusions: Sputum MMP-9 concentrations in COPD are directly associated with the extent of emphysema measured
by CT and MMP-9 expression levels are inversely associated with DLco. These findings support a role for MMP-9 in the
pathogenesis of COPD.
Keywords: MMP-9, MMP-9 expression, COPD, Computed tomography
Findings
Inappropriate expression and excessive activity of several
matrix metalloproteinases (MMP), including MMP-9 [1,2]
has been implicated in the tissue destructive processes asso-
ciated with chronic lung diseases including COPD [2-7]. In-
creased sputum MMP-9 protein concentrations and/or
activity are reported in current smokers with COPD com-
pared to healthy smokers [8,9]. However, a definitive role of
MMP-9 in the development of emphysema is uncertain.
For example, mice deficient in MMP-9 develop the same
degree of cigarette smoke-induced inflammation and air-
space enlargement as control mice and human macro-
phages MMP-9 mRNA is present in areas of lung
irrespective of the presence of emphysema [10]. Neverthe-
less circulating monocytes from subjects with advanced
emphysema on computed tomography (CT) produced
more MMP-9 than controls [10]. In previous clinical stud-
ies there is a lack of information about concentrations, ac-
tivities and expression of MMP-9 in well characterized
patients with COPD and it is unknown whether MMP-9
activity is linked to disease severity. The aim of the study
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was to test the hypothesis that MMP-9 concentrations and
activity in COPD are associated with disease severity as
assessed by lung function and computed tomography.
Methods
Subjects
A cross sectional study was performed in subjects with
COPD and healthy controls as part of the Glasgow
COPD and Asthma Biomarker study [7]. Clinical,
physiological and immunological plus imaging (COPD
groups only) measurements were performed at baseline.
Participants were recruited with mild, moderate and se-
vere COPD (GOLD stages I (n = 14), II (n = 23) and III
(n = 16) [11]; (both current smokers and ex-smokers),
and healthy smokers and never smokers, defined as vol-
unteers with no known respiratory disease, no chronic
respiratory symptoms and normal spirometry.
The West Glasgow Research Ethics Committee approved
the study and all patients gave written informed consent.
Measurements
Spirometry was performed according to American Thor-
acic Society guidelines [12]. Lung volumes and diffusing
capacity for carbon monoxide (DLco) were performed
using the body box technique (Zan500 Body Plethysmog-
raphy, nSpire Health Limited, Hertford, UK). Sputum in-
duction was performed as previously described [7]. CT
scans of the Chest were performed at full inspiration using
16 slice Brightspeed and 64 slice Lightspeed (GE CT scan-
ner, Milwaukee, Wisconsin, USA) with the following pa-
rameters: 120 KV, 100 mAs, collimation 1mm, reconstruc-
tion slice thickness 0.65mm, reconstruction slice separation
0.5mm, pitch of 1 and the data was reconstructed with a
CHST filter. All scans were evaluated centrally at the Uni-
versity of Edinburgh. Emphysema was quantified as the
percentage of lung CT voxels below a threshold of −950
Hounsfield Units-% low attenuation areas (LAA)-950,
using the software Pulmonary Workstation 2.0 (VIDA
Diagnostics, Iowa City, IA, USA) as described previously
[13-15]. MMP-9 ELISA and MMP-9 activity kits (fluores-
cence resonance energy transfer (FRET) method) were
supplied by R&D Systems Europe Ltd. (Cat. Nos. DMP900
and F9M00 respectively; Abingdon, UK). Assays were
performed in accordance with the instructions provided;
however the activity assay was read kinetically over 4 hours
as this showed better reproducibility than an end-point
read-out. Samples were not chemically activated with
amino-phenyl mercuric acetate to allow estimation of en-
dogenous enzyme activity. The MMP-9 assays were vali-
dated for sputum. Samples spiked with exogenous MMP-9
(Lot#40011-70; Wyeth, USA) showed bias of <11% with
101-110% recovery; inter-assay CV was <8.8% and intra-
assay CV was <7.9%; concentrations were stable up to 5
freeze-thaw cycles. Sputum cell MMP-9 expression levels
(Affymetrix number 203936_s_at, on U133 + 2 chips) were
measured in RNA isolated from airway inflammatory infil-
trate cells harvested from induced sputum in healthy
never smokers (n = 15), healthy smokers (n = 13), smokers
with moderate to severe COPD (n = 15) and ex-smokers
with moderate to severe COPD (n = 12). Expression levels
were compared after global normalisation.
Analysis
Variables were summarised as median (inter-quartile
range). Values were compared between patient sub-
groups using two-sample Wilcoxon tests or Kruskal-
Wallis test. Associations of MMP-9 with biomarkers
were assessed using Spearman rank correlation coeffi-
cient with bootstrap 95% confidence intervals. All ana-
lyses were carried out in R version 2.11.0 [16].
Results
Baseline demographics
Demographics and baseline characteristics are previously
reported [7]. Briefly, median (IQR) age [years] of COPD
volunteers was 65 (61.2, 68.9), healthy never smokers 49.9
(42.1, 55.8) and healthy smokers 53.3 (45.1, 57.8). In
healthy never smokers FEV1% predicted median (IQR)
was 105.5 (95.2, 115.0) and in healthy smokers this was
92.5 (87.5, 100.2). Lung function in the COPD group was
as follows: median (IQR) post-bronchodilator FEV1% pre-
dicted, 65.0 (48.0-80.0); post-bronchodilator FEV1/FVC ra-
tio, 64.0 (50.0-67.0); DLCO% predicted, 60.0 (47.5-70.0).
Sputum MMP-9 concentrations and activity
Sputum MMP-9 concentrations were increased in
COPD subjects compared to healthy never smokers (p =
Table 1 Sputum MMP-9 concentrations and activity in
sputum fluid from patients with COPD and healthy
controls [Median (IQR)]
MMP-9 (ng/mL) MMP-9 activity (ng/mL)
Healthy
Control
All 49.80 (26.35, 136.50) 18.90 (12.50, 38.35)
Never smoker 34.05 (24.45, 131.00) 16.60 (12.50, 28.42)
Smoker 69.00 (38.65, 184.00) 18.90 (13.40, 46.45)
p value 1 p = 0.161 p = 0.285
COPD All 137.50 (45.52, 362.95) 26.65 (12.50, 51.85)
Ex- smoker 214.75 (101.12, 445.05) 42.10 (26.02, 116.10)
Smoker 56.10 (28.90, 190.70) 12.50 (12.50, 32.52)
p value 2 p = 0.002 p < 0.001
p value 3 p = 0.007 p = 0.187
p value 4 p = 0.343 p = 0.787
p value 5 p < 0.001 p < 0.001
p value 6 p = 0.617 p = 0.086
1 Healthy smokers vs. healthy never smoker; 2 COPD smokers vs COPD ex-smokers;
3 All COPD subjects vs. healthy never smokers; 4 All COPD subjects vs.
healthy smokers;
5 COPD ex-smokers vs. healthy never smokers; 6 COPD smokers vs. healthy smokers.
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0.007), but were similar to healthy smokers (p = 0.343)
(Table 1). Sputum MMP-9 enzyme activity was increased
in ex-smokers with COPD compared to healthy never
smokers (p < 0.001). Ex-smokers with COPD had higher
concentrations and activity of sputum MMP-9 than
current smokers with COPD (p = 0.002 and p < 0.001 re-
spectively). Sputum MMP-9 concentrations and activity
did not differ significantly between mild, moderate and
severe COPD groups (data not shown). The MMP-9
protein concentration and activity did not correlate sig-
nificantly with FEV1 or DLco% predicted. The extent of
emphysema (% LAA −950) was significantly associated
with sputum MMP-9 protein concentration [r = 0.442
(0.171, 0.634), p = 0.020,)] (Figure 1) and MMP-9 activity
[r = 0.447 (0.219, 0.643), p = 0.010]. Sputum MMP-9
protein concentration, r = 0.724 (0.557, 0.839), p <
0.001,)] and MMP-9 activity, r = 0.682 (0.520, 0.800), p <
0.001, were associated with the percentage of sputum
neutrophils. The sputum MMP-9 protein concentration
correlated with sputum cell MMP-9 mRNA expression
[r = 0.510 (0.292, 0.664), p < 0.001].
Sputum MMP-9 mRNA expression
Sputum cell MMP-9 expression levels [median (IQR)] nor-
malized fluorescent intensity units]) were significantly
greater in ex-smokers with COPD, [4622 (3161, 5962)],
current smokers with COPD, [5085 (4378, 9338)] and
healthy smokers, [4111 (1623, 6202)] compared with
healthy never smokers, [1650 (1023, 3443)]; (p = 0.001 for
each). Sputum MMP-9 expression levels correlated
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Figure 1 Correlation of sputum MMP-9 concentration (ng/ml) with computed tomography measure of emphysema [the low
attenuation areas below −950 Hounsfield Units taken as an index of emphysema (% LAA −950) [r = 0.442 (0.171, 0.634), p = 0.020)].
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Figure 2 Correlation of sputum MMP-9 mRNA expression and diffusing capacity for carbon monoxide (DLco) % predicted [r = −0.399
(−0.539, -0.102), p = 0.048].
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negatively with post-bronchodilator FEV1% predicted
[r = −0.530, (95% CI −0.686, -0.327), p < 0.001], post-
bronchodilator FEV1/FVC [(r = −0.551 (−0.701, -0.354], p <
0.001], and DLco [r = −0.399 (−0.539, -0.102), p = 0.048],
(Figure 2) but were not significantly associated with the CT
extent of emphysema [r = 0.266 (−0.020, 0.446), p = 0.115].
Discussion
This study found that sputum MMP-9 concentrations
and mRNA expression in COPD are significantly greater
than in healthy never-smokers, that sputum MMP-9
concentrations are directly associated with the extent of
emphysema measured by CT and that higher MMP-9
expression levels are associated with greater airflow ob-
struction and reduced diffusing capacity. Taken together,
these findings provide indirect evidence for a link be-
tween MMP-9 and disease severity in COPD.
Previous studies have reported increased MMP-9 protein
concentrations and/or activity in current smokers with
COPD compared to healthy smokers [8,9]. In contrast to
the finding from these studies we found that sputum
MMP-9 concentrations and activity in COPD subjects
were similar to healthy smokers. There are differences in
the severity of disease and smoking status between these
studies. The patients with COPD studied previously [8,9]
had in general more severe disease compared to the partic-
ipants in our study, which could explain the different re-
sults [17]. Both current and ex-smokers with COPD were
recruited to the present study, whereas previous studies in-
cluded only current smokers with COPD [8,9]. Smoking
status is however unlikely to explain the different results as
ex-smokers had higher MMP-9 levels and activity than
current smokers with COPD. The ex-smokers with COPD
in the present study had more severe disease, as assessed
by the extent of emphysema on CT, which may explain the
higher sputum MMP-9 concentrations in this group.
The severity of COPD, when assessed by the extent of
emphysema on CT scanning, but not by spirometry values,
was significantly associated with sputum MMP-9 concen-
trations and activity. We found no significant association
between sputum MMP-9 levels and DLco; although the
extent of emphysema measured by CT often correlates
with DLco in COPD, this association is not always found.
The findings of an association of greater MMP-9 expres-
sion in moderate to severe disease with greater airflow ob-
struction and reduced diffusing capacity as well as more
extensive emphysema on CT scanning with MMP-9 con-
centrations suggests a role for MMP-9 in the pathogenesis
of emphysema. Alternatively, increased sputum MMP-9
may be a marker of disease severity in patients who
already have emphysema. Long-term clinical trials of
MMP-9 inhibitors in COPD would help establish whether
blocking MMP-9 activity attenuates the development and
progression of emphysema. Previously, we reported that
sputum MMP-12 concentrations and activity in patients
with COPD are directly associated with the extent of em-
physema measured by CT [7] suggesting that blocking
both MMP-9 and MMP-12 may be more effective than
inhibiting either MMP-9 or MMP-12 alone.
In conclusion, disease severity in COPD when assessed
by the extent of emphysema measured by CT is directly
associated with sputum MMP-9 concentrations. Inter-
ventions directed at inhibiting MMP-9 activity, either
alone or in combination with MMP-12 blockers, should
be investigated for their potential to attenuate the devel-
opment or progression of emphysema.
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